drugset / Trial / NCT02555943
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
Phase 2/3
Completed
23 enrolled
Humanity and Health Research Centre
Beijing 302 Hospital · collabNanfang Hospital, Southern Medical University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective study to determine the incidence, morbidity, mortality and predisposing factors for the reactivation of hepatitis B virus replication during direct anti-HCV treatment of HCV/HBV co-infection patients.
Timeline
- Start
- 2015-02
- Primary completion
- 2021-05
- Completion
- 2021-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclatasvir | Small molecule | 60 mg | Oral |
| Subject | Entecavir | Small molecule | 0.5 mg | — |
| Subject | Ledipasvir/Sofosbuvir | Unknown | 90 mg | Oral |
| Subject | Ledipasvir/Sofosbuvir | Unknown | 400 mg | Oral |
| Subject | Ritonavir | Other / unclassified | — | — |
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |
| Subject | Tenofovir disoproxil fumarate | Small molecule | — | — |
| Subject | dasabuvir | Small molecule | — | — |
| Subject | ombitasvir | Small molecule | — | — |
| Subject | paritaprevir | Small molecule | — | — |